The Small Molecule GMX1778 Is a Potent Inhibitor of NAD + Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors

Poly(ADP-ribose): novel functions for an old molecule

Schreiber, V., Dantzer, F., Amé, J., & de MURCIA, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1963 · Cited by 1,917 · see citing works

Requirement of NAD and <i>SIR2</i> for Life-Span Extension by Calorie Restriction in <i>Saccharomyces cerevisiae</i>

Lin, S.-J., Defossez, P.-A., & Guarente, L. (2000) · Science · doi:10.1126/science.289.5487.2126 · Cited by 1,775 · see citing works

The Sir2 Family of Protein Deacetylases

Blander, G., & Guarente, L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073651 · Cited by 1,496 · see citing works

A gene expression database for the molecular pharmacology of cancer

Scherf, U., Ross, D. T., Waltham, M. C., Smith, L. H., Lee, J. K., Tanabe, L. K., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450 · see citing works

Cloning and Characterization of the cDNA Encoding a Novel Human pre-B-Cell Colony-enhancing Factor

Samal, B. B., Sun, Y., Stearns, G., Xie, C., Suggs, S. V., & McNiece, I. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.2.1431 · Cited by 1,025 · see citing works

The NAD Biosynthesis Pathway Mediated by Nicotinamide Phosphoribosyltransferase Regulates Sir2 Activity in Mammalian Cells

Revollo, J. R., Grimm, A. A., & Imai, S.-I. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408388200 · Cited by 1,010 · see citing works

Nampt/PBEF/Visfatin Regulates Insulin Secretion in β Cells as a Systemic NAD Biosynthetic Enzyme

Revollo, J. R., Körner, A., Mills, K. F., Satoh, A., Wang, T., Garten, A., Dasgupta, B., Sasaki, Y., Wolberger, C., Townsend, R. R., et al. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.09.003 · Cited by 911 · see citing works

The power to reduce: pyridine nucleotides—small molecules with a multitude of functions

Pollak, N., Dölle, C., & Ziegler, M. (2007) · Biochemical Journal · doi:10.1042/bj20061638 · Cited by 730 · see citing works

Nuclear ADP-Ribosylation Reactions in Mammalian Cells: Where Are We Today and Where Are We Going?

Hassa, P. O., Haenni, S. S., Elser, M., & Hottiger, M. O. (2006) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00040-05 · Cited by 682 · see citing works

FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.

Hasmann, M., & Schemainda, I. (2003) · PubMed · Cited by 618 · see citing works

Alkylating DNA damage stimulates a regulated form of necrotic cell deathPreprint

Zong, W., Ditsworth, D., Bauer, D. E., Wang, Z., & Thompson, C. B. (2004) · Genes & Development · doi:10.1101/gad.1199904 · Cited by 618 · see citing works

Polyglutamation of methotrexate. Is methotrexate a prodrug?

Chabner, B. A., Allegra, C. J., Curt, G. A., Clendeninn, N. J., Baram, J., Koizumi, S., Drake, J. C., & Jolivet, J. (1985) · Journal of Clinical Investigation · doi:10.1172/jci112088 · Cited by 461 · see citing works

Physiological functions of cyclic ADP-ribose and NAADP as calcium messengers

Lee, H. C. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.317 · Cited by 433 · see citing works

Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme

Wang, T., Zhang, X., Bheda, P., Revollo, J. R., Imai, S., & Wolberger, C. (2006) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1114 · Cited by 305 · see citing works

Enzymology of NAD+ homeostasis in man

Magni, G., Amici, A., Emanuelli, M., Orsomando, G., Raffaelli, N., & Ruggieri, S. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3161-1 · Cited by 289 · see citing works

Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents

Khan, J., Tao, X., & Tong, L. (2006) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1105 · Cited by 274 · see citing works

NAD+ and NADH in cellular functions and cell death

Ying, W. (2006) · Frontiers in bioscience · doi:10.2741/2038 · Cited by 250 · see citing works

Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery

Khan, J., Forouhar, F., Tao, X., & Tong, L. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.5.695 · Cited by 174 · see citing works

A profile of differentially expressed genes in primary colorectal cancer using suppression subtractive hybridization

Hufton, S. E., Moerkerk, P. T. M., Brandwijk, R. J. M. G. E., A, A. P. D. B., Arends, J., & Hoogenboom, H. R. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01578-1 · Cited by 164 · see citing works

Target validation for genomics using peptide‐specific phage antibodies: A study of five gene products overexpressed in colorectal cancer

B, J. R. V. B., Moerkerk, P. T. M., Gerbers, A. J., A, A. P. D. B., Arends, J., Hoogenboom, H. R., & Hufton, S. E. (2002) · International Journal of Cancer · doi:10.1002/ijc.10584 · Cited by 134 · see citing works

Anticancer agent CHS-828 inhibits cellular synthesis of NAD

Olesen, U. H., Christensen, M. K., Björkling, F., Jäättelä, M., Jensen, P. B., Sehested, M., & Nielsen, S. J. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.01.019 · Cited by 122 · see citing works

Crystal Structure of Visfatin/Pre-B Cell Colony-enhancing Factor 1/Nicotinamide Phosphoribosyltransferase, Free and in Complex with the Anti-cancer Agent FK-866

Kim, M., Lee, J. H., Kim, H., Park, S.-J., Kim, S. H., Kang, G. B., Lee, Y. S., Kim, J. B., Kim, K. K., Suh, S. W., et al. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.06.082 · Cited by 122 · see citing works

CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo.

Hjarnaa, P. V., Jonsson, E. W., Latini, S., Dhar, S., Larsson, R., Bramm, E., Skov, T., & Binderup, L. (1999) · PubMed · Cited by 115 · see citing works

PBEF1/NAmPRTase/Visfatin: A potential malignant astrocytoma/glioblastoma serum marker with prognostic value

Reddy, P., Srikantha, U., Thota, B., Tandon, A., Pandey, P. P., Hegde, A. S., Balasubramaniam, A., Chandramouli, B. A., Santosh, V., Rao, M. R. S., et al. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.5.5663 · Cited by 111 · see citing works

Borrowing from Biology

Nazar, R. N., & Robb, E. J. (2007) · Science · doi:10.1126/science.318.5850.565c · Cited by 109 · see citing works

Mapping the role of NAD metabolism in prevention and treatment of carcinogenesis

Jacobson, E. L., Shieh, W.-R., & Huang, A. C. (1999) · Springer eBooks · doi:10.1007/978-1-4419-8740-2_10 · Cited by 86 · see citing works

Molecular Functions of BRCA1 in the DNA Damage Response

Scully, R., Xie, A., & Nagaraju, G. (2004) · Cancer Biology & Therapy · doi:10.4161/cbt.3.6.842 · Cited by 84 · see citing works

BID-D59A Is a Potent Inducer of Apoptosis in Primary Embryonic Fibroblasts

Sarig, R., Zaltsman, Y., Marcellus, R. C., Flavell, R. A., Mak, T. W., & Gross, A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210296200 · Cited by 70 · see citing works

Preclinical development of the nicotinamide phosphoribosyl transferase inhibitor prodrug GMX1777

Beauparlant, P., Bédard, D., Bernier, C., Chan, H. H. L., Gilbert, K., Goulet, D., Gratton, M., Lavoie, M., Roulston, A., Turcotte, É., et al. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283287c20 · Cited by 67 · see citing works

Mapping the role of NAD metabolism inprevention and treatment of carcinogenesis

Jacobson, E. L., Jacobson, E. L., Jacobson, E. L., Jacobson, E. L., Shieh, W.-R., & Huang, A. C. (1999) · Molecular and Cellular Biochemistry · doi:10.1023/a:1006960126369 · Cited by 63 · see citing works

Biochemical pathways of apoptosis: nicotinamide adenine dinucleotide-deficient cells are resistant to tumor necrosis factor or ultraviolet light activation of the 24-kD apoptotic protease and DNA fragmentation.

Wright, S. C., Wei, Q., Kinder, D. H., & Larrick, J. W. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.2.463 · Cited by 61 · see citing works

Nicotinamide Adenine Dinucleotide Based Therapeutics

Pankiewicz, K. W., Chen, L., Petrelli, R., Felczak, K., Gao, G., Bonnac, L. F., Yu, J., & Bennett, E. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708783885282 · Cited by 53 · see citing works

Multiparametric evaluation of apoptosis: Effects of standard cytotoxic agents and the cyanoguanidine CHS 828

Lövborg, H., Nygren, P., & Larsson, R. L. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.521.3.5 · Cited by 52 · see citing works

Anticancer agent CHS 828 suppresses nuclear factor‐κB activity in cancer cells through downregulation of IKK activity

Olsen, L. S., Hjarnaa, P. V., Latini, S., Holm, P. K., Larsson, R. L., Bramm, E., Binderup, L., & Madsen, M. W. (2004) · International Journal of Cancer · doi:10.1002/ijc.20255 · Cited by 45 · see citing works

Leukemia inhibitory factor is a mediator of Escherichia coli lipopolysaccharide-induced acute thymic atrophy

Sempowski, G. D., Rhein, M. E., Scearce, R. M., & Haynes, B. F. (2002) · European Journal of Immunology · doi:10.1002/1521-4141(200211)32:11 · Cited by 38 · see citing works

Activity of CHS 828 in primary cultures of human hematological and solid tumors in vitro

Åleskog, A., Hassan, S. B., Hovstadius, P., Kristensen, J., Höglund, M., Tholander, B., Binderup, L., Larsson, R. L., & Jonsson, E. (2001) · Anti-Cancer Drugs · doi:10.1097/00001813-200111000-00005 · Cited by 23 · see citing works

Action of a novel anticancer agent, CHS 828, on mouse fibroblasts: increased sensitivity of cells lacking poly (ADP-Ribose) polymerase-1.

Lövborg, H., Wojciechowski, J., Larsson, R. L., & Węsierska‐Gądek, J. (2002) · PubMed · Cited by 22 · see citing works

Mitogenic enhancement of purine base phosphoribosylation in Swiss mouse 3T3 cells

Becker, M. A., Dicker, P., & Rozengurt, E. (1983) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1983.244.3.c288 · Cited by 19 · see citing works

Changes in NAD/ADP-ribose metabolism in rectal cancer

Yalçıntepe, L., Şener, L. T., Sener, A., Yetkın, G., Tiryaki, D., & Bermek, E. (2005) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2005000300006 · Cited by 18 · see citing works

A Fluorescence-Based Coupling Reaction for Monitoring the Activity of Recombinant Human NAD Synthetase

Bembenek, M. E., Kuhn, E. W., Mallender, W. D., Pullen, L., Li, P., & Parsons, T. F. (2005) · Assay and Drug Development Technologies · doi:10.1089/adt.2005.3.533 · Cited by 14 · see citing works

Modulation of pyridyl cyanoguanidine (CHS 828) induced cytotoxicity by 3-aminobenzamide in U-937 GTB cells

Lövborg, H., Martinsson, P., Gullbo, J., Ekelund, S., Nygren, P., & Larsson, R. L. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00890-0 · Cited by 13 · see citing works

Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore

Fleming, F. F., Yao, L., Ravikumar, P. C., Funk, L. A., & Shook, B. C. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100762r · Cited by 1,764 · see citing works

NAD+ Metabolism and the Control of Energy Homeostasis: A Balancing Act between Mitochondria and the Nucleus

Cantó, C., Menzies, K. J., & Auwerx, J. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.05.023 · Cited by 1,648 · see citing works

Targeting Metabolism for Cancer Therapy

Luengo, A., Gui, D. Y., & Vander Heiden, M. G. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.08.028 · Cited by 971 · see citing works

The NAD metabolome — a key determinant of cancer cell biology

Chiarugi, A., Dölle, C., Felici, R., & Ziegler, M. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3340 · Cited by 645 · see citing works

Organization of GC/MS and LC/MS metabolomics data into chemical libraries

DeHaven, C. D., Evans, A. M., Dai, H., & Lawton, K. A. (2010) · Journal of Cheminformatics · doi:10.1186/1758-2946-2-9 · Cited by 601 · see citing works

NAD+ metabolism, stemness, the immune response, and cancer

Navas, L. E., & Carnero, A. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00354-w · Cited by 529 · see citing works

Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion

Tateishi, K., Wakimoto, H., Iafrate, A. J., Tanaka, S., Loebel, F., Lelic, N., Wiederschain, D., Bedel, O., Deng, G., Zhang, B., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.11.006 · Cited by 433 · see citing works

The Lkb1 metabolic sensor maintains haematopoietic stem cell survival

Gurumurthy, S., Xie, S. Z.-J., Alagesan, B., Kim, J., Yusuf, R. Z., Sáez, B., Tzatsos, A., Ozsolak, F., Milos, P. M., Ferrari, F., et al. (2010) · Nature · doi:10.1038/nature09572 · Cited by 391 · see citing works

Role of NAD+ in regulating cellular and metabolic signaling pathways

Amjad, S., Nisar, S., Bhat, A. A., Shah, A. R., Frenneaux, M. P., Fakhro, K. A., Haris, M., Reddy, R. D., Patay, Z. J., Baur, J. A., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101195 · Cited by 394 · see citing works

Pathways and Subcellular Compartmentation of NAD Biosynthesis in Human Cells

Nikiforov, A., Dölle, C., Niere, M., & Ziegler, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.213298 · Cited by 326 · see citing works

Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer

Sampath, D., Zabka, T. S., Misner, D. L., O’Brien, T., & Dragovich, P. S. (2015) · Pharmacology &amp; Therapeutics · doi:10.1016/j.pharmthera.2015.02.004 · Cited by 258 · see citing works

A rise in NAD precursor nicotinamide mononucleotide (NMN) after injury promotes axon degeneration

Di Stefano, M., Nascimento-Ferreira, I., Orsomando, G., Mori, V, Gilley, J., Brown, R., Janeckova, L., Vargas, M. E., Worrell, L. A., Loreto, A., et al. (2015) · Cell Death &amp; Differentiation · doi:10.1038/cdd.2014.164 · Cited by 246 · see citing works

NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response

Wang, B., Hasan, M. K., Alvarado, E., Yuan, H., Wu, H., & Chen, W. (2010) · Oncogene · doi:10.1038/onc.2010.468 · Cited by 244 · see citing works

Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells

Jones, C. L., Stevens, B. M., Pollyea, D. A., Culp‐Hill, R., Reisz, J. A., Nemkov, T. G., Gehrke, S. A., Gamboni, F., Krug, A., Winters, A. C., et al. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.07.021 · Cited by 242 · see citing works

Macrophages provide a transient muscle stem cell niche via NAMPT secretion

Ratnayake, D., Nguyen, P. D., Rossello, F. J., Wimmer, V. C., Tan, J. L., Galvis, L. A., Julier, Z., Wood, A. J., Boudier, T., Isiaku, A. I., et al. (2021) · Nature · doi:10.1038/s41586-021-03199-7 · Cited by 227 · see citing works

NAD Metabolism in Cancer Therapeutics

Yaku, K., Okabe, K., Hikosaka, K., & Nakagawa, T. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00622 · Cited by 229 · see citing works

The human NAD metabolome: Functions, metabolism and compartmentalization

Nikiforov, A. A., Kulikova, V., & Ziegler, M. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1028612 · Cited by 214 · see citing works

NAMPT and NAPRT: Two Metabolic Enzymes With Key Roles in Inflammation

Audrito, V., Messana, V. G., & Deaglio, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00358 · Cited by 209 · see citing works

SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis

Li, Y., Matsumori, H., Nakayama, Y., Osaki, M., Kojima, H., Kurimasa, A., Ito, H., Mori, S., Katoh, M., Oshimura, M., et al. (2010) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01460.x · Cited by 189 · see citing works

Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies

Balanis, N. G., Sheu, K. M., Esedebe, F. N., Patel, S. J., Smith, B. A., Park, J. W., Alhani, S., Gomperts, B. N., Huang, J., Witte, O. N., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.06.005 · Cited by 172 · see citing works

Pharmacological Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, in Human Cancer Cells

Tan, B., Young, D. A., Lu, Z.-H., Wang, T., Meier, T. I., Shepard, R. L., Roth, K. D. W., Zhai, Y. W., Huss, K., Kuo, M., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.394510 · Cited by 178 · see citing works

Endogenous and xenobiotic metabolic stability of primary human hepatocytes in long-term 3D spheroid cultures revealed by a combination of targeted and untargeted metabolomics

Vorrink, S. U., Ullah, S., Schmidt, S., Nandania, J., Velagapudi, V., Beck, O., Ingelman‐Sundberg, M., & Lauschke, V. M. (2017) · The FASEB Journal · doi:10.1096/fj.201601375r · Cited by 172 · see citing works

Boosting NAD+ with a small molecule that activates NAMPT

Gardell, S. J., Hopf, M., Khan, A., Dispagna, M., Hampton Sessions, E., Falter, R., Kapoor, N., Brooks, J., Culver, J., Petucci, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11078-z · Cited by 169 · see citing works

CD73 Protein as a Source of Extracellular Precursors for Sustained NAD+ Biosynthesis in FK866-treated Tumor Cells

Grozio, A., Sociali, G., Sturla, L., Caffa, I., Soncini, D., Salis, A., Raffaelli, N., De Flora, A., Nencioni, A., & Bruzzone, S. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.470435 · Cited by 158 · see citing works

Targeting cancer metabolism – aiming at a tumour's sweet-spot

Jones, N. P., & Schulze, A. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.12.017 · Cited by 162 · see citing works

Myc-Driven glycolysis is a therapeutic target in glioblastoma

Tateishi, K., Iafrate, A. J., Ho, Q., Curry, W. T., Batchelor, T. T., Flaherty, K. T., Onozato, M. L., Lelic, N., Sundaram, S., Cahill, D. P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2274 · Cited by 160 · see citing works

Medicinal Chemistry of Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors

Galli, U., Travelli, C., Massarotti, A., Fakhfouri, G., Rahimian, R., Tron, G. C., & Genazzani, A. A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4001049 · Cited by 155 · see citing works

Overcoming Temozolomide Resistance in Glioblastoma via Dual Inhibition of NAD+ Biosynthesis and Base Excision Repair

Goellner, E. M., Grimme, B., Brown, A. R., Lin, Y., Wang, X., Sugrue, K. F., Mitchell, L., Trivedi, R. N., Tang, J.-B., & Sobol, R. W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3213 · Cited by 155 · see citing works

NAD+ salvage pathway in cancer metabolism and therapy

Kennedy, B. E., Sharif, T., Martell, E., Dai, C., Kim, Y., Lee, P. W. K., & Gujar, S. A. (2016) · Pharmacological Research · doi:10.1016/j.phrs.2016.10.027 · Cited by 144 · see citing works

Synthetic lethality of PARP and NAMPT inhibition in triple-negative breast cancer cells

Bajrami, I., Kigozi, A., Van Weverwijk, A., Brough, R., Frankum, J., Lord, C. J., & Ashworth, A. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201201250 · Cited by 136 · see citing works

Sirtuin deacylases: a molecular link between metabolism and immunity

Preyat, N., & Léo, O. (2013) · Journal of Leukocyte Biology · doi:10.1189/jlb.1112557 · Cited by 133 · see citing works

Epigenetic polypharmacology: A new frontier for epi‐drug discovery

Tomaselli, D., Lucidi, A., Rotili, D., & Mai, A. (2019) · Medicinal Research Reviews · doi:10.1002/med.21600 · Cited by 126 · see citing works

Extracellular nicotinamide phosphoribosyltransferase, a new cancer metabokine

Grolla, A. A., Travelli, C., Genazzani, A. A., & Sethi, J. K. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13505 · Cited by 119 · see citing works

Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors

Dong, G., Chen, W., Wang, X., Yang, X., Xu, T., Wang, P., Zhang, W., Rao, Y., Miao, C., & Sheng, C. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00467 · Cited by 117 · see citing works

Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes

Neggers, J. E., Kwanten, B., Dierckx, T., Noguchi, H., Voet, A. R. D., Bral, L., Minner, K., Massant, B., Kint, N., Delforge, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02349-8 · Cited by 113 · see citing works

Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy

Heske, C. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01514 · Cited by 110 · see citing works

Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair

Piacente, F., Caffa, I., Ravera, S., Sociali, G., Passalacqua, M., Vellone, V. G., Becherini, P., Reverberi, D., Monacelli, F., Ballestrero, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3079 · Cited by 113 · see citing works

Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin

Carbone, F., Liberale, L., Bonaventura, A., Vecchié, A., Casula, M., Cea, M., Monacelli, F., Caffa, I., Bruzzone, S., Montecucco, F., et al. (2017) · Comprehensive physiology · doi:10.1002/cphy.c160029 · Cited by 107 · see citing works

Metabolomics in the clinic: A review of the shared and unique features of untargeted metabolomics for clinical research and clinical testing

Kennedy, A. D., Wittmann, B. M., Evans, A. M., Miller, L. A. D., Toal, D. R., Lonergan, S. C., Elsea, S. H., & Pappan, K. L. (2018) · Journal of Mass Spectrometry · doi:10.1002/jms.4292 · Cited by 104 · see citing works

Review of various NAMPT inhibitors for the treatment of cancer

Wei, Y., Xiang, H., & Zhang, W. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.970553 · Cited by 105 · see citing works

The role of extracellular and intracellular Nicotinamide phosphoribosyl-transferase in cancer: Diagnostic and therapeutic perspectives and challenges

Dalamaga, Μ., Christodoulatos, G. S., & Mantzoros, C. S. (2018) · Metabolism · doi:10.1016/j.metabol.2018.01.001 · Cited by 92 · see citing works

NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone

Moore, Z., Chakrabarti, G., Luo, X., Ali, A., Hu, Z., Fattah, F. J., Vemireddy, R., DeBerardinis, R. J., Brekken, R. A., & Boothman, D. A. (2015) · Cell Death and Disease · doi:10.1038/cddis.2014.564 · Cited by 90 · see citing works

The Role of Inflammation in Brain Cancer

Sowers, J. L., Johnson, K. M., Conrad, C. C., Patterson, J. T., & Sowers, L. C. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-0348-0837-8_4 · Cited by 90 · see citing works

Blocking Non-enzymatic Functions by PROTAC-Mediated Targeted Protein Degradation

Sun, D., Zhang, J., Dong, G., He, S., & Sheng, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01159 · Cited by 88 · see citing works

Structure-Based Discovery of Novel Amide-Containing Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors

Zheng, X., Bauer, P., Baumeister, T., Buckmelter, A. J., Caligiuri, M., Clodfelter, K. H., Han, B., Ho, Y., Kley, N., Lin, J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4008664 · Cited by 88 · see citing works

Extracellular NAD+ enhances PARP-dependent DNA repair capacity independently of CD73 activity

Wilk, A. M., Hayat, F., Cunningham, R., Li, J., Garavaglia, S., Zamani, L., Ferraris, D. M., Sýkora, P., Andrews, J., Clark, J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57506-9 · Cited by 88 · see citing works

Metabolomics Analysis of Metabolic Effects of Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibition on Human Cancer Cells

Tolstikov, V., Nikolayev, A., Dong, S., Zhao, G., & Kuo, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114019 · Cited by 86 · see citing works

Intracellular NAD+ depletion enhances bortezomib-induced anti-myeloma activity

Cagnetta, A., Cea, M., Calimeri, T., Acharya, C., Fulciniti, M., Tai, Y., Hideshima, T., Chauhan, D., Zhong, M. Y., Patrone, F., et al. (2013) · Blood · doi:10.1182/blood-2013-02-483511 · Cited by 86 · see citing works

Loss of NAPRT1 Expression by Tumor-Specific Promoter Methylation Provides a Novel Predictive Biomarker for NAMPT Inhibitors

Shames, D. S., Elkins, K., Walter, K., Holcomb, T., Du, P., Mohl, D. A., Xiao, Y., Pham, T., Haverty, P. M., Liederer, B. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1186 · Cited by 85 · see citing works

Targeting glucose transport and the NAD pathway in tumor cells with STF-31: a re-evaluation

Kraus, D., Reckenbeil, J., Veit, N., Kürpig, S., Meisenheimer, M., Beier, I., Stark, H., Winter, J., & Probstmeier, R. (2018) · Cellular Oncology · doi:10.1007/s13402-018-0385-5 · Cited by 83 · see citing works

Retinal Toxicity, in vivo and in vitro, Associated with Inhibition of Nicotinamide Phosphoribosyltransferase

Zabka, T. S., Singh, J., Dhawan, P., Liederer, B. M., Oeh, J., Kauss, M. A., Xiao, Y., Zak, M., Lin, T., McCray, B., et al. (2014) · Toxicological Sciences · doi:10.1093/toxsci/kfu268 · Cited by 83 · see citing works

Metabolomics in cell culture—A strategy to study crucial metabolic pathways in cancer development and the response to treatment

Halama, A. (2014) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2014.09.002 · Cited by 82 · see citing works

Nicotinamide Phosphoribosyltransferase Acts as a Metabolic Gate for Mobilization of Myeloid-Derived Suppressor Cells

Travelli, C., Consonni, F. M., Sangaletti, S., Storto, M., Morlacchi, S., Grolla, A. A., Galli, U., Tron, G. C., Portararo, P., Rimassa, L., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1544 · Cited by 83 · see citing works

Dependence of Tumor Cell Lines and Patient-Derived Tumors on the NAD Salvage Pathway Renders Them Sensitive to NAMPT Inhibition with GNE-618

Xiao, Y., Elkins, K., Durieux, J., Lee, L. B., Oeh, J., Yang, L., Liang, X., DelNagro, C., Tremayne, J. R., Kwong, M., et al. (2013) · Neoplasia · doi:10.1593/neo.131304 · Cited by 82 · see citing works

Structure-Based Identification of Ureas as Novel Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors

Zheng, X., Bauer, P., Baumeister, T., Buckmelter, A. J., Caligiuri, M., Clodfelter, K. H., Han, B., Ho, Y., Kley, N., Lin, J., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400186h · Cited by 81 · see citing works

NAMPT Is the Cellular Target of STF-31-Like Small-Molecule Probes

Adams, D., Ito, D., Rees, M. G., Seashore-Ludlow, B. A., Puyang, X., Ramos, A. H., Cheah, J. H., Clemons, P. A., Warmuth, M., Zhu, P., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb500347p · Cited by 80 · see citing works

A Preclinical Study on the Rescue of Normal Tissue by Nicotinic Acid in High-Dose Treatment with APO866, a Specific Nicotinamide Phosphoribosyltransferase Inhibitor

Olesen, U. H., Thougaard, A., Jensen, P. B., & Sehested, M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1130 · Cited by 79 · see citing works

NAD Biosynthesis in Humans - Enzymes, Metabolites and Therapeutic Aspects

Dölle, C., Skoge, R. H., VanLinden, M. R., & Ziegler, M. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113136660206 · Cited by 78 · see citing works

OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis

Korotchkina, L. G., Kazyulkin, D. N., Komarov, P. G., Polinsky, A., Andrianova, E. L., Joshi, S. P., Gupta, M., Vujcic, S., Kononov, E., Toshkov, I. A., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0692-5 · Cited by 79 · see citing works

Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT) Activity by Small Molecule GMX1778 Regulates Reactive Oxygen Species (ROS)-mediated Cytotoxicity in a p53- and Nicotinic Acid Phosphoribosyltransferase1 (NAPRT1)-dependent Manner

Cerna, D., Li, H., Flaherty, S. M., Takebe, N., Coleman, C. N., & Yoo, S. S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.357301 · Cited by 78 · see citing works

Depletion of the Central Metabolite NAD Leads to Oncosis-mediated Cell Death

Nagro, C. J. D., Xiao, Y., Rangell, L. K., Reichelt, M., & O’Brien, T. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.580159 · Cited by 81 · see citing works

Next-Generation NAMPT Inhibitors Identified by Sequential High-Throughput Phenotypic Chemical and Functional Genomic Screens

Matheny, C., Wei, M. C., Bassik, M. C., Donnelly, A. J., Kampmann, M., 岩崎, 正., Piloto, O., Solow-Cordero, D. E., Bouley, D. M., Rau, R. E., et al. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.09.014 · Cited by 76 · see citing works

Temozolomide and Other Potential Agents for the Treatment of Glioblastoma Multiforme

Nagasawa, D. T., Chow, F. E., Yew, A. Y., Kim, W. B., Cremer, N., & Yang, I. (2012) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2012.01.007 · Cited by 76 · see citing works

PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma

Fons, N. R., Sundaram, R. K., Breuer, G. A., Peng, S., McLean, R. L., Kalathil, A., Schmidt, M. S., Carvalho, D. M., Mackay, A. G., Jones, C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11732-6 · Cited by 77 · see citing works

A fluorometric assay for high-throughput screening targeting nicotinamide phosphoribosyltransferase

Zhang, R.-Y., Ye, Q., Lv, X., Wang, P., Xu, T., Zhang, L., & Miao, C. (2011) · Analytical Biochemistry · doi:10.1016/j.ab.2010.12.035 · Cited by 72 · see citing works

Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia

Mitchell, S. R., Larkin, K. T. M., Grieselhuber, N. R., Lai, T.-H., Cannon, M. J., Orwick, S. J., Sharma, P., Asemelash, Y., Zhang, P., Goettl, V. M., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018024182 · Cited by 70 · see citing works

Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas

Olesen, U. H., Hastrup, N., & Sehested, M. (2011) · Apmis · doi:10.1111/j.1600-0463.2011.02733.x · Cited by 70 · see citing works

Advances in NAD-Lowering Agents for Cancer Treatment

Ghanem, M. S., Monacelli, F., & Nencioni, A. (2021) · Nutrients · doi:10.3390/nu13051665 · Cited by 69 · see citing works

Nicotinamide Adenine Dinucleotide (NAD) Metabolism as a Relevant Target in Cancer

Navas, L. E., & Carnero, A. (2022) · Cells · doi:10.3390/cells11172627 · Cited by 68 · see citing works

Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors

Duarte-Pereira, S., Pereira‐Castro, I., Silva, S. S., Correia, M. G., Neto, C., da Costa, L. T., Amorim, A., & Silva, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.6538 · Cited by 68 · see citing works

NAD-Biosynthetic and Consuming Enzymes as Central Players of Metabolic Regulation of Innate and Adaptive Immune Responses in Cancer

Audrito, V., Managò, A., Gaudino, F., Sorci, L., Messana, V. G., Raffaelli, N., & Deaglio, S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01720 · Cited by 64 · see citing works

Supplementation of Nicotinic Acid with NAMPT Inhibitors Results in Loss of In Vivo Efficacy in NAPRT1-Deficient Tumor Models

O’Brien, T., Oeh, J., Xiao, Y., Liang, X., Vanderbilt, A. N., Qin, A., Yang, L., Lee, L. B., Ly, J., Cosino, E., et al. (2013) · Neoplasia · doi:10.1593/neo.131718 · Cited by 62 · see citing works

Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery

Chen, W., Dong, G., Wu, Y., Zhang, W., Miao, C., & Sheng, C. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00414 · Cited by 62 · see citing works

Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity

Travelli, C., Aprile, S., Rahimian, R., Grolla, A. A., Rogati, F., Bertolotti, M., Malagnino, F., Paola, R. D., Impellizzeri, D., Fusco, R., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01392 · Cited by 61 · see citing works

Dynamics of NAD-metabolism: everything but constant

Opitz, C. A., & Heiland, I. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150133 · Cited by 58 · see citing works

Targeting Metabolic Changes in Cancer: Novel Therapeutic Approaches

Bobrovnikova-Marjon, E. V., & Hurov, J. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112344 · Cited by 55 · see citing works

Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway

Feng, J., Yan, P.-F., Zhao, H., Zhang, F., Zhao, W., & Feng, M. (2016) · BioMed Research International · doi:10.1155/2016/1450843 · Cited by 55 · see citing works

Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells

Tan, B., Dong, S., Shepard, R. L., Kays, L. M., Roth, K. D. W., Geeganage, S., Kuo, M., & Zhao, G. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.632141 · Cited by 54 · see citing works

Nicotinamide Phosphoribosyl Transferase (Nampt) Is Required for De Novo Lipogenesis in Tumor Cells

Bowlby, S. C., Thomas, M. J., D’Agostino, R. B., & Kridel, S. J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040195 · Cited by 54 · see citing works

Chemical Proteomics Identifies Nampt as the Target of CB30865, An Orphan Cytotoxic Compound

Fleischer, T. C., Murphy, B. R., Flick, J. S., Terry-Lorenzo, R. T., Gao, Z.-H., Davis, T., McKinnon, R. S., Ostanin, K., Willardsen, J. A., & Boniface, J. J. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.05.008 · Cited by 54 · see citing works

Nicotinamide adenine dinucleotide (NAD+): essential redox metabolite, co-substrate and an anti-cancer and anti-ageing therapeutic target

Griffiths, H. B. S., Williams, C., King, S. J., & Allison, S. J. (2020) · Biochemical Society Transactions · doi:10.1042/bst20190033 · Cited by 55 · see citing works

Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

Olesen, U. H., Petersen, J. G., Garten, A., Kieß, W., Yoshino, J., Imai, S., Christensen, M. K., Fristrup, P., Thougaard, A., Björkling, F., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-677 · Cited by 53 · see citing works

New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology

Roulston, A., & Shore, G. C. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1052180 · Cited by 54 · see citing works

Metabolomics as a Key Integrator for “Omic” Advancement of Personalized Medicine and Future Therapies

Eckhart, A. D., Beebe, K. D., & Milburn, M. (2012) · Clinical and Translational Science · doi:10.1111/j.1752-8062.2011.00388.x · Cited by 52 · see citing works

Structural and Biochemical Analyses of the Catalysis and Potency Impact of Inhibitor Phosphoribosylation by Human Nicotinamide Phosphoribosyltransferase

Oh, A., Ho, Y., Zak, M., Liu, Y., Chen, X., Yuen, P., Zheng, X., Liu, Y., Dragovich, P. S., & Wang, W. (2014) · ChemBioChem · doi:10.1002/cbic.201402023 · Cited by 51 · see citing works

Targeted Delivery of Cytotoxic NAMPT Inhibitors Using Antibody–Drug Conjugates

Neumann, C. S., Olivas, K. C., Anderson, M. E., Cochran, J. H., Jin, S., Li, F., Loftus, L. V., Meyer, D. W., Neale, J. R., Nix, J. C., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0643 · Cited by 51 · see citing works

Recycling Nicotinamide. The Transition-State Structure of Human Nicotinamide Phosphoribosyltransferase

Burgos, E. S., Vetticatt, M. J., & Schramm, V. L. (2013) · Journal of the American Chemical Society · doi:10.1021/ja310180c · Cited by 50 · see citing works

Cancer cell metabolic plasticity allows resistance to NAMPT inhibition but invariably induces dependence on LDHA

Thongon, N., Zucal, C., D’Agostino, V., Tebaldi, T., Ravera, S., Zamporlini, F., Piacente, F., Moschoi, R., Raffaelli, N., Quattrone, A., et al. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0174-7 · Cited by 50 · see citing works

Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT)

Zheng, X., Bair, K. W., Bauer, P., Baumeister, T., Bowman, K. K., Buckmelter, A. J., Caligiuri, M., Clodfelter, K. H., Feng, Y., Han, B., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.08.074 · Cited by 49 · see citing works

Novel assay for simultaneous measurement of pyridine mononucleotides synthesizing activities allows dissection of the NAD + biosynthetic machinery in mammalian cells

Zamporlini, F., Ruggieri, S., Mazzola, F., Amici, A., Orsomando, G., & Raffaelli, N. (2014) · FEBS Journal · doi:10.1111/febs.13050 · Cited by 48 · see citing works

Software Techniques for Enabling High-Throughput Analysis of Metabolomic Datasets

Corey, D., Anne, M., Dai, H., & Khutorskaya, I. A. (2012) · InTech eBooks · doi:10.5772/31277 · Cited by 47 · see citing works

Synergy between the NAMPT inhibitor GMX1777(8) and pemetrexed in non-small cell lung cancer cells is mediated by PARP activation and enhanced NAD consumption

Chan, M., Gravel, M., Bramoullé, A., Bridon, G., Avizonis, D., Shore, G. C., & Roulston, A. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0809 · Cited by 46 · see citing works

Discovery of a Highly Selective NAMPT Inhibitor That Demonstrates Robust Efficacy and Improved Retinal Toxicity with Nicotinic Acid Coadministration

Zhao, G., Green, C. F., Hui, Y., Prieto, L., Shepard, R. L., Dong, S., Wang, T., Tan, B., Gong, X., Kays, L. M., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0674 · Cited by 46 · see citing works

Research into cancer metabolomics: Towards a clinical metamorphosis

Olivares, O., Däbritz, J. H. M., King, A., Gottlieb, E., & Halsey, C. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.09.008 · Cited by 45 · see citing works

Nicotinamide Phosphoribosyltransferase Inhibitors, Design, Preparation, and Structure–Activity Relationship

Christensen, M. K., Erichsen, K. D., Olesen, U. H., Tjørnelund, J., Fristrup, P., Thougaard, A., Nielsen, S. J., Sehested, M., Jensen, P. B., Loža, E., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4009949 · Cited by 44 · see citing works

Fragment-Based Identification of Amides Derived from trans-2-(Pyridin-3-yl)cyclopropanecarboxylic Acid as Potent Inhibitors of Human Nicotinamide Phosphoribosyltransferase (NAMPT)

Giannetti, A. M., Zheng, X., Skelton, N. J., Wang, W., Bravo, B. J., Bair, K. W., Baumeister, T., Cheng, E., Crocker, L., Feng, Y., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm4015108 · Cited by 44 · see citing works

Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors

Zak, M., Yuen, P., Liu, X., Patel, S. D., Sampath, D., Oeh, J., Liederer, B. M., Wang, W., O’Brien, T., Xiao, Y., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00697 · Cited by 44 · see citing works

Discovery of potent and efficacious urea-containing nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with reduced CYP2C9 inhibition properties

Gunzner, J. L., Zhao, G., Bauer, P., Baumeister, T., Buckmelter, A. J., Caligiuri, M., Clodfelter, K. H., Fu, B., Han, B., Ho, Y., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.04.040 · Cited by 43 · see citing works

NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma

Peterse, E. F. P., van den Akker, B. E. W. M., Niessen, B., Oosting, J., Suijker, J., de Jong, Y., Danen, E. H. J., Cleton-Jansen, A., & Bovée, J. V. M. G. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0293 · Cited by 43 · see citing works

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

Okumura, S., Sasaki, T., Minami, Y., & Ohsaki, Y. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318233d686 · Cited by 42 · see citing works

The Small Molecule GMX1778 Is a Potent Inhibitor of NAD Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid

Tumors, P. D., Shore, G. C., & Beauparlant, P. (2009)

NAPRT1 and p53 Status in Cancer and Normal Cells Modulate Induction of ROS Induced by GMX1777/1778: Implication for Synthetic Lethality in Tumors Defective in NAPRT1 and p53

Yoo, S., Cerna, D., Li, H., Flaherty, S. M., Takebe, N., & Coleman, C. N. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.07.1527 · Cited by 1 · see citing works

GMX1777: a novel inhibitor of NAD+ biosynthesis via inhibition of nicotinamide phosphoribosyl transferase.

Roulston, A., Watson, M. H., Bernier, C., Chan, H. H. L., Gratton, M., Jang, A., Koch, E. M., Lavoie, M., Paquette, D., Mitchell, M. W., et al. (2007) · Molecular Cancer Therapeutics · Cited by 3 · see citing works

Abstract B98: Induction of metabolic and oxidative stresses by the novel inhibitor of NAD+ biosynthesis, GMX 1778, for specific killing of human glioblastomas

Yoo, S. S., Cerna, D., Carter, D. J., Flaherty, S. M., Li, H., Takebe, N., & Watson, M. H. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-09-b98

Abstract 2127: Identification of a novel NAMPT inhibition resistance mechanism utilizing the de novo NAD+ biosynthesis pathway

Guo, J. Q., Tse, C., & Pappano, W. N. (2016) · Cancer Research · doi:10.1158/1538-7445.am2016-2127